Compugen Ltd (CGEN) 7.00 $CGEN
AppSense Announces 2014 Partners of the Year in North America
Business Wire - Mon Apr 20, 9:43AM CDT
AppSense, the leading provider of enterprise workspace management solutions, today named its 2014 North American Partners of the Year at the inaugural AppSense Elevate Partner Conference. One partner was awarded in each region for revenue and excelling in their commitment to growing their AppSense business practices and core competencies.
CGEN: 7.00 (-0.09)
Compugen Obtains Rights to Use Biological Systems and Materials from the US National Institutes of Health
Business Wire - Tue Apr 14, 6:02AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that it has obtained rights to use in-house certain biological systems and materials, developed by the U.S. National Institutes of Health (NIH), for purposes of advancing the research and development of the Company's multiple immuno-oncology programs toward future clinical evaluation.
CGEN: 7.00 (-0.09)
Compugen to Present at Two Immuno-Oncology Conferences in April
Business Wire - Mon Apr 06, 6:10AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Anat Cohen-Dayag, PhD, President and Chief Executive Officer, Compugen, will present aspects of the Company's immune checkpoint programs at two oncology conferences in Boston this month.
CGEN: 7.00 (-0.09)
Compugen to move to new digs by year-end
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 8:59AM CDT
CGEN: 7.00 (-0.09)
Compugen Announces Planned Relocation of Headquarters to Larger Facilities
Business Wire - Thu Mar 19, 6:09AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced the planned relocation by year-end of its Tel-Aviv headquarters, along with its Israeli research and discovery operations, to substantially larger facilities. The new facilities, now being prepared according to Compugen's specifications, will support the ongoing growth of the Company and the further advancement of its novel immune checkpoint programs for cancer immunotherapy. The new facilities will be located in the Azrieli Holon Business Center about 12 miles south of Compugen's current location and will double the available space for the Company's corporate offices and labs.
CGEN: 7.00 (-0.09)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
COWN: 5.81 (+0.03), CHA: 77.53 (+3.31), CHL: 75.00 (+0.71), CGEN: 7.00 (-0.09), GCA: 7.66 (-0.31)
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
CSV: 24.11 (unch), AVA: 34.08 (+0.27), ANH: 5.24 (+0.02), CGEN: 7.00 (-0.09), ARIS: 3.26 (-0.01)
Compugen to Present at Two Oncology Conferences in March
Business Wire - Mon Mar 02, 6:09AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that it will present aspects of its immune checkpoint related research at two oncology conferences this month.
CGEN: 7.00 (-0.09)
Moving Average Crossover Alert: Compugen (CGEN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 8:57AM CST
Moving Average Crossover Alert: Compugen (CGEN)
CGEN: 7.00 (-0.09)
Facebook Is Not Expensive - Cramer's Lightning Round (2/20/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Feb 23, 4:54AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, February 20. Bullish Calls: Facebook (NASDAQ: FB ): "The stock has been stalled and we'll probably find out it's due to insider selling," said...
KMI: 44.34 (-0.23), WSO.B: 121.70 (unch), PGR: 26.86 (+0.05), JNJ: 101.08 (+0.62), FB: 81.53 (-0.88), CGEN: 7.00 (-0.09), SFL: 15.63 (-0.01), WSO: 124.17 (-0.20), REGN: 480.09 (+0.01), TRV: 103.95 (+0.47)
'Mad Money' Lightning Round: J&J Must Get Its Game Back
at The Street - Sat Feb 21, 5:00AM CST
Cramer says Facebook is not expensive, Watsco is a winner and take Regeneron over Compugen.
PGR: 26.86 (+0.05), KMI: 44.34 (-0.23), JNJ: 101.08 (+0.62), FB: 81.53 (-0.88), CGEN: 7.00 (-0.09), WSO: 124.17 (-0.20), REGN: 480.09 (+0.01), TRV: 103.95 (+0.47)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Feb 20, 7:21PM CST
When the euphoria surrounding Greece fades, Cramer will be watching stocks of companies that have great earnings.
KMI: 44.34 (-0.23), MNST: 141.78 (+1.42), VRX: 210.42 (+1.03), WSO: 124.17 (-0.20), M: 66.99 (-0.43), PGR: 26.86 (+0.05), JNJ: 101.08 (+0.62), ESRX: 87.34 (+0.45), TGT: 82.70 (+0.77), DPZ: 113.96 (+4.73), HAWK: 35.67 (-0.03), GOOGL: 573.66 (+16.20), TWTR: 50.82 (-0.59), REGN: 480.09 (+0.01), TRV: 103.95 (+0.47), HD: 113.70 (-0.26), AVP: 9.02 (+0.03), DISH: 69.91 (+0.30), DIN: 103.05 (+1.95), MHR: 2.26 (-0.14), CBRL: 142.08 (+0.67), LB: 91.20 (-0.45), CGEN: 7.00 (-0.09), JCP: 8.41 (-0.07), EL: 82.26 (-0.19), TOL: 36.80 (+0.75), NRG: 25.53 (+0.82), ROST: 104.38 (-0.13), CRM: 67.83 (-0.64)
A Look at the Latest Occurrences in the Biotechnology Sector: Special Research on China Biologic Products, Compugen, Curis, CytRx, and DBV Technologies
PR Newswire - Mon Feb 16, 7:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
CBPO: 98.59 (-0.35), CRIS: 2.96 (-0.01), DBVT: 26.29 (+0.41), CYTR: 5.13 (-0.13), CGEN: 7.00 (-0.09)
Direction of Market Influences: Special Research on Insperity, Compugen, Aeropostale, Starwood Hotels & Resorts, and Coca-Cola
PR Newswire - Wed Feb 11, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
KO: 40.89 (-0.06), NSP: 50.80 (-0.91), CGEN: 7.00 (-0.09), ARO: 3.50 (+0.04), HOT: 83.13 (-0.21)
Compugen's (CGEN) CEO Anat Cohen-Dayag on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 12:49PM CST
CGEN: 7.00 (-0.09)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.59 (-0.05), ZIOP: 10.81 (-0.39), XON: 44.10 (-0.91), BIOC: 2.88 (-0.22), KKR: 23.39 (-0.15), NBG: 1.23 (+0.06), ARO: 3.50 (+0.04), ANFI: 8.95 (-0.03), HOT: 83.13 (-0.21), COUP: 13.03 (-0.10), URBN: 41.90 (-0.49), VSTM: 10.05 (+0.01), SYN: 2.33 (+0.01), ANTH: 5.20 (+0.31), SALE: 19.03 (+0.02), CGEN: 7.00 (-0.09), DF: 16.83 (-0.03), CJJD: 4.01 (+0.27), MERU: 1.25 (-0.03)
Compugen reports 4Q loss
Automated Insights - Tue Feb 10, 6:36AM CST
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Tuesday reported a loss of $1.5 million in its fourth quarter.
CGEN: 7.00 (-0.09)
Compugen beats by $0.08, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:16AM CST
CGEN: 7.00 (-0.09)
Compugen Ltd. Reports Fourth Quarter and Calendar 2014 Results
Business Wire - Tue Feb 10, 6:10AM CST
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the fourth quarter and year ended December 31, 2014.
CGEN: 7.00 (-0.09)
Compugen: A Biotech With Many Rewarding Catalysts
Clinically Sound Investor - at Seeking Alpha - Tue Feb 10, 4:23AM CST
CGEN: 7.00 (-0.09)
AppSense Announces 2014 Partners of the Year in North America
Business Wire - Mon Apr 20, 9:43AM CDT
AppSense, the leading provider of enterprise workspace management solutions, today named its 2014 North American Partners of the Year at the inaugural AppSense Elevate Partner Conference. One partner was awarded in each region for revenue and excelling in their commitment to growing their AppSense business practices and core competencies.
CGEN: 7.00 (-0.09)
Compugen Obtains Rights to Use Biological Systems and Materials from the US National Institutes of Health
Business Wire - Tue Apr 14, 6:02AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that it has obtained rights to use in-house certain biological systems and materials, developed by the U.S. National Institutes of Health (NIH), for purposes of advancing the research and development of the Company's multiple immuno-oncology programs toward future clinical evaluation.
CGEN: 7.00 (-0.09)
Compugen to Present at Two Immuno-Oncology Conferences in April
Business Wire - Mon Apr 06, 6:10AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Anat Cohen-Dayag, PhD, President and Chief Executive Officer, Compugen, will present aspects of the Company's immune checkpoint programs at two oncology conferences in Boston this month.
CGEN: 7.00 (-0.09)
Compugen to move to new digs by year-end
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 8:59AM CDT
CGEN: 7.00 (-0.09)
Compugen Announces Planned Relocation of Headquarters to Larger Facilities
Business Wire - Thu Mar 19, 6:09AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced the planned relocation by year-end of its Tel-Aviv headquarters, along with its Israeli research and discovery operations, to substantially larger facilities. The new facilities, now being prepared according to Compugen's specifications, will support the ongoing growth of the Company and the further advancement of its novel immune checkpoint programs for cancer immunotherapy. The new facilities will be located in the Azrieli Holon Business Center about 12 miles south of Compugen's current location and will double the available space for the Company's corporate offices and labs.
CGEN: 7.00 (-0.09)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
COWN: 5.81 (+0.03), CHA: 77.53 (+3.31), CHL: 75.00 (+0.71), CGEN: 7.00 (-0.09), GCA: 7.66 (-0.31)
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
CSV: 24.11 (unch), AVA: 34.08 (+0.27), ANH: 5.24 (+0.02), CGEN: 7.00 (-0.09), ARIS: 3.26 (-0.01)
Compugen to Present at Two Oncology Conferences in March
Business Wire - Mon Mar 02, 6:09AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that it will present aspects of its immune checkpoint related research at two oncology conferences this month.
CGEN: 7.00 (-0.09)
Moving Average Crossover Alert: Compugen (CGEN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 8:57AM CST
Moving Average Crossover Alert: Compugen (CGEN)
CGEN: 7.00 (-0.09)
Facebook Is Not Expensive - Cramer's Lightning Round (2/20/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Feb 23, 4:54AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, February 20. Bullish Calls: Facebook (NASDAQ: FB ): "The stock has been stalled and we'll probably find out it's due to insider selling," said...
KMI: 44.34 (-0.23), WSO.B: 121.70 (unch), PGR: 26.86 (+0.05), JNJ: 101.08 (+0.62), FB: 81.53 (-0.88), CGEN: 7.00 (-0.09), SFL: 15.63 (-0.01), WSO: 124.17 (-0.20), REGN: 480.09 (+0.01), TRV: 103.95 (+0.47)
'Mad Money' Lightning Round: J&J Must Get Its Game Back
at The Street - Sat Feb 21, 5:00AM CST
Cramer says Facebook is not expensive, Watsco is a winner and take Regeneron over Compugen.
PGR: 26.86 (+0.05), KMI: 44.34 (-0.23), JNJ: 101.08 (+0.62), FB: 81.53 (-0.88), CGEN: 7.00 (-0.09), WSO: 124.17 (-0.20), REGN: 480.09 (+0.01), TRV: 103.95 (+0.47)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Feb 20, 7:21PM CST
When the euphoria surrounding Greece fades, Cramer will be watching stocks of companies that have great earnings.
KMI: 44.34 (-0.23), MNST: 141.78 (+1.42), VRX: 210.42 (+1.03), WSO: 124.17 (-0.20), M: 66.99 (-0.43), PGR: 26.86 (+0.05), JNJ: 101.08 (+0.62), ESRX: 87.34 (+0.45), TGT: 82.70 (+0.77), DPZ: 113.96 (+4.73), HAWK: 35.67 (-0.03), GOOGL: 573.66 (+16.20), TWTR: 50.82 (-0.59), REGN: 480.09 (+0.01), TRV: 103.95 (+0.47), HD: 113.70 (-0.26), AVP: 9.02 (+0.03), DISH: 69.91 (+0.30), DIN: 103.05 (+1.95), MHR: 2.26 (-0.14), CBRL: 142.08 (+0.67), LB: 91.20 (-0.45), CGEN: 7.00 (-0.09), JCP: 8.41 (-0.07), EL: 82.26 (-0.19), TOL: 36.80 (+0.75), NRG: 25.53 (+0.82), ROST: 104.38 (-0.13), CRM: 67.83 (-0.64)
A Look at the Latest Occurrences in the Biotechnology Sector: Special Research on China Biologic Products, Compugen, Curis, CytRx, and DBV Technologies
PR Newswire - Mon Feb 16, 7:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
CBPO: 98.59 (-0.35), CRIS: 2.96 (-0.01), DBVT: 26.29 (+0.41), CYTR: 5.13 (-0.13), CGEN: 7.00 (-0.09)
Direction of Market Influences: Special Research on Insperity, Compugen, Aeropostale, Starwood Hotels & Resorts, and Coca-Cola
PR Newswire - Wed Feb 11, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
KO: 40.89 (-0.06), NSP: 50.80 (-0.91), CGEN: 7.00 (-0.09), ARO: 3.50 (+0.04), HOT: 83.13 (-0.21)
Compugen's (CGEN) CEO Anat Cohen-Dayag on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 12:49PM CST
CGEN: 7.00 (-0.09)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.59 (-0.05), ZIOP: 10.81 (-0.39), XON: 44.10 (-0.91), BIOC: 2.88 (-0.22), KKR: 23.39 (-0.15), NBG: 1.23 (+0.06), ARO: 3.50 (+0.04), ANFI: 8.95 (-0.03), HOT: 83.13 (-0.21), COUP: 13.03 (-0.10), URBN: 41.90 (-0.49), VSTM: 10.05 (+0.01), SYN: 2.33 (+0.01), ANTH: 5.20 (+0.31), SALE: 19.03 (+0.02), CGEN: 7.00 (-0.09), DF: 16.83 (-0.03), CJJD: 4.01 (+0.27), MERU: 1.25 (-0.03)
Compugen reports 4Q loss
Automated Insights - Tue Feb 10, 6:36AM CST
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Tuesday reported a loss of $1.5 million in its fourth quarter.
CGEN: 7.00 (-0.09)
Compugen beats by $0.08, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:16AM CST
CGEN: 7.00 (-0.09)
Compugen Ltd. Reports Fourth Quarter and Calendar 2014 Results
Business Wire - Tue Feb 10, 6:10AM CST
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the fourth quarter and year ended December 31, 2014.
CGEN: 7.00 (-0.09)
Compugen: A Biotech With Many Rewarding Catalysts
Clinically Sound Investor - at Seeking Alpha - Tue Feb 10, 4:23AM CST
CGEN: 7.00 (-0.09)
